GALECTIN-1 IMPROVES COGNITION IN AN ANIMAL MODEL OF ALZHEIMER?S DISEASE AND PREVENTS BLOOD-BRAIN BARRIER DISRUPTION CAUSED BY EXPOSURE TO AMYLOID-Β IN VITRO

PRESA, JESSICA; POMILIO C; GREGOSA, AMAL; VINUESA A; BEAUQUIS J; RABINOVICH G; SARAVIA F

Mar del Plata

Congreso; Reunion Anual de la Sociedad Argentina de Investigacion Clinica; 2018

SAIC

Alzheimer?s disease (AD) is a neurodegenerative disorder associatedwith an imbalance of production and clearance of amyloid-β peptides(Aβ), generating amyloid plaques in the brain. Neurofibrillarytangles and inflammation in cortex and hippocampus are recognizedhallmarks of the disease, in addition to microvascular alterations anddysfunction of the blood-brain barrier (BBB). The glycan-bindingprotein galectin-1 (Gal1) was demonstrated to have neuroprotectiveeffects in other neurodegenerative diseases, associated with inflammatorymodulation. It can act on immune and endothelial cells inperipheral and central nervous system. We have shown that Gal1treatment improved cognition in PDAPPJ20, mouse model of AD ,assessed by novel location recognition test (p